iPACK and Femoral Triangle Block for Pain Control in ACL Reconstruction

November 16, 2026 updated by: moazzam ali, Combined Military Hospital Quetta

Analgesic Efficacy and Functional Recovery of Adding iPACK to Femoral Triangle Block in Anterior Cruciate Ligament Reconstruction

The goal of this clinical trial is to learn if adding an iPACK block (a nerve block for the back of the knee) to a femoral triangle block improves pain control and knee function after surgery in adults aged 18 to 50 years undergoing anterior cruciate ligament (ACL) reconstruction. It will also learn about the safety of the combined blocks. The main questions it aims to answer are:

Does adding an iPACK block to a femoral triangle block lower postoperative pain scores over the first 48 hours? Does the combined block reduce the amount of opioid pain medication needed and delay the time to first rescue pain medication? Does the combined block improve early knee function (quadriceps strength, knee range of motion, and patient-reported knee scores) without causing muscle weakness or other complications?

Researchers will compare a femoral triangle block plus an iPACK block to a femoral triangle block alone (with a sham procedure to keep patients unaware of their group) to see if the added iPACK block provides better pain relief and recovery after ACL reconstruction.

Participants will:

Receive either a femoral triangle block plus an iPACK block, or a femoral triangle block alone, under ultrasound guidance before or after surgery Rate their pain at rest and during movement at 6, 12, 24, and 48 hours after surgery Have their pain medication use, quadriceps strength, knee movement, and time to first walking recorded during the hospital stay Complete knee function questionnaires (IKDC, Lysholm, and KOOS) before surgery and at follow-up visits at 2 weeks, 6 weeks, and 3 months Be monitored for side effects such as nausea, vomiting, falls, and nerve-related problems

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 50 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Adults aged 18 to 50 years, of either sex, Scheduled for primary, unilateral, elective arthroscopic anterior cruciate ligament (ACL) reconstruction (autograft, e.g., hamstring or patellar tendon),American Society of Anesthesiologists (ASA) physical status I or II, Body mass index (BMI) of 35 kg/m² or less Planned spinal or general anesthesia Able to understand and use the Numeric Rating Scale (NRS) for pain, and able to comply with postoperative assessments and follow-up visits Willing and able to provide written informed consent

Exclusion Criteria:

  • Patient refusal or inability to provide informed consent Known allergy or hypersensitivity to local anesthetics or other study medications Coagulopathy, or use of anticoagulants or antiplatelet agents that contraindicate regional anesthesia Infection at the planned block injection site Pre-existing neurological deficit or neuropathy in the operative limb Revision ACL surgery, multiligament reconstruction, or major concomitant procedures (e.g., osteotomy, cartilage restoration) Chronic opioid use or chronic pain conditions Contraindication to paracetamol or NSAIDs that would prevent standardized multimodal analgesia Psychiatric or cognitive disorder that limits pain assessment Pregnancy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Group FTB

An ultrasound-guided femoral triangle block performed on the operative limb with the patient supine. A high-frequency linear transducer is placed transversely over the anterior thigh, below the inguinal crease, at the level where the sartorius muscle crosses the femoral artery and the femoral triangle is bordered by the sartorius, adductor longus, and inguinal ligament. A 22-gauge, 80 to 100 mm echogenic block needle is advanced in-plane, lateral to medial, to the lateral side of the femoral artery, beneath the fascia iliaca and above the iliopsoas muscle, and local anesthetic is deposited around the femoral artery to target the saphenous nerve, the nerve to the vastus medialis, and the anterior femoral cutaneous branches.

Experimental: Group FTB with Ipack

An ultrasound-guided iPACK block performed in addition to the FTB, The patient is positioned supine with the knee flexed and hip externally rotated. A curvilinear or linear transducer is placed in the popliteal fossa at the level of the femoral condyles, and the popliteal artery and posterior surface of the femur are identified. A 22-gauge, 80 to 100 mm block needle is advanced in-plane from the medial side to the plane between the popliteal artery and the femoral shaft or condyles, posterior to the artery and anterior to the posterior knee capsule. After negative aspiration, 15 to 20 mL of the same local anesthetic is injected

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
postoperative pain intensity at rest and on movement, measured by the Numeric Rating Scale (NRS, 0 to 10)
Time Frame: 6, 12, 24, and 48 hours after the end of surgery
6, 12, 24, and 48 hours after the end of surgery
Total opioid consumption
Time Frame: 48 hours after surgery
48 hours after surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 15, 2026

Primary Completion (Estimated)

December 1, 2026

Study Completion (Estimated)

December 1, 2026

Study Registration Dates

First Submitted

November 16, 2026

First Submitted That Met QC Criteria

November 16, 2026

First Posted (Actual)

November 20, 2026

Study Record Updates

Last Update Posted (Actual)

November 20, 2026

Last Update Submitted That Met QC Criteria

November 16, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • ipack/2026

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.